

GAndrei Dan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2330817/publications.pdf>

Version: 2024-02-01

100
papers

10,248
citations

136950

32
h-index

49909

87
g-index

102
all docs

102
docs citations

102
times ranked

9927
citing authors

#	ARTICLE	IF	CITATIONS
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	2.2	5,583
2	2018 ESC Guidelines for the diagnosis and management of syncope. <i>European Heart Journal</i> , 2018, 39, 1883-1948.	2.2	1,200
3	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014, 16, 308-319.	1.7	280
4	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2017, 19, 1589-1623.	1.7	208
5	Device-detected subclinical atrial tachyarrhythmias: definition, implications and managementâ€”an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2017, 19, 1556-1578.	1.7	186
6	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. <i>Europace</i> , 2015, 17, 24-31.	1.7	164
7	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2015, 17, 1197-1214.	1.7	160
8	â€”Real-Worldâ€™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. <i>American Journal of Medicine</i> , 2014, 127, 519-529.e1.	1.5	144
9	Antiarrhythmic drugsâ€”clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> , 2016, 18, 721-732.	1.7	144
10	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	1.7	138
11	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. <i>Europace</i> , 2015, 17, 1777-1786.	1.7	128
12	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.	1.7	124
13	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2015, 17, 1747-1769.	1.7	119
14	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac y Electrofisiologia (SOLEACE). <i>Europace</i> , 2017, 19, 465-511.	1.7	118
15	Contemporary stroke prevention strategies in 11â€”%096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.	1.7	118
16	Syncope Unit: rationale and requirement â€” the European Heart Rhythm Association position statement endorsed by the Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1325-1340.	1.7	98
17	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Europace</i> , 2018, 20, 1399-1421.	1.7	75
18	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021, 23, 174-183.	1.7	74

#	ARTICLE	IF	CITATIONS
19	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 7-8.	1.7	72
20	Heart failure in patients with atrial fibrillation in Europe: a report from the <sc>EURObservational</sc> Research Programme Pilot survey on Atrial Fibrillation. <i>European Journal of Heart Failure</i> , 2015, 17, 570-582.	7.1	68
21	The wearable cardioverter-defibrillator: current technology and evolving indications. <i>Europace</i> , 2017, 19, 335-345.	1.7	65
22	“Real-world” management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme “Atrial Fibrillation (EORP-AF) General Pilot Registry. <i>Europace</i> , 2016, 18, 648.1-657.	1.7	61
23	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). <i>Europace</i> , 2019, 21, 1603-1604.	1.7	61
24	Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS). <i>Europace</i> , 2017, 19, 1909-1922.	1.7	50
25	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. <i>Europace</i> , 2017, 19, 1439-1448.	1.7	47
26	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.	1.7	47
27	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. <i>Europace</i> , 2019, 21, 1459-1467.	1.7	45
28	Implications of geographical variation on clinical outcomes of cardiovascular trials. <i>American Heart Journal</i> , 2012, 164, 303-312.	2.7	44
29	Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging. <i>IJC Heart and Vasculature</i> , 2018, 21, 11-15.	1.1	43
30	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015, 17, 194-206.	1.7	41
31	Stroke prevention in atrial fibrillation and “real world” adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. <i>Scientific Reports</i> , 2016, 6, 20432.	3.3	40
32	Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients. <i>Liver International</i> , 2015, 35, 2547-2555.	3.9	35
33	Sacubitril/valsartan eligibility and outcomes in the ESC “EORP” HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM “HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	7.1	35
34	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>Europace</i> , 2017, 19, euw150.	1.7	32
35	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. <i>International Journal of Cardiology</i> , 2018, 271, 68-74.	1.7	30
36	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 70-84.	3.3	25

#	ARTICLE	IF	CITATIONS
37	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2018, 20, 895-896.	1.7	24
38	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021, 19, 256.	5.5	22
39	Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. <i>Annals of Medicine</i> , 2021, 53, 17-25.	3.8	18
40	Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 368-373.	2.1	17
41	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. <i>Advances in Therapy</i> , 2017, 34, 2043-2057.	2.9	17
42	Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. <i>Europace</i> , 2018, 20, 1382-1387.	1.7	15
43	Contemporary management of patients with syncope in clinical practice: an EHRA physician-based survey. <i>Europace</i> , 2020, 22, 980-987.	1.7	14
44	Systemic sclerosis biomarkers discovered using mass-spectrometry-based proteomics: a systematic review. <i>Biomarkers</i> , 2014, 19, 345-355.	1.9	13
45	Thyroid hormones and the heart. <i>Heart Failure Reviews</i> , 2016, 21, 357-359.	3.9	11
46	Determinants of Prolonged Length of Hospital Stay of Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3715.	2.4	11
47	Influence of decision aids on oral anticoagulant prescribing among physicians: a randomised trial. <i>European Journal of Clinical Investigation</i> , 2017, 47, 649-658.	3.4	10
48	Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients. <i>Egyptian Rheumatologist</i> , 2017, 39, 1-6.	1.0	10
49	Management of patients with ventricular arrhythmias and prevention of sudden cardiac deathâ€”translating guidelines into practice: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2018, 20, f249-f253.	1.7	10
50	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019, 21, 1116-1125.	1.7	10
51	Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 254, 136-141.	1.7	8
52	Stroke Risk Scores as Predictors of Severe Outcomes in Atrial Fibrillation: A Comprehensive Review. <i>American Journal of Therapeutics</i> , 2021, 28, e319-e334.	0.9	7
53	2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronisation Therapy. <i>European Cardiology Review</i> , 2021, 16, e55.	2.2	7
54	Deceleration and Acceleration Capacities in Risk Stratification for Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease. <i>American Journal of Therapeutics</i> , 2017, 24, e44-e51.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. European Journal of Clinical Investigation, 2022, 52, e13773.	3.4	6
56	Following up adult patients with tetralogy of fallot: The role of echocardiography. Journal of Clinical Ultrasound, 2017, 45, 79-95.	0.8	5
57	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the Edoxaban versus warfarin in subjects Undergoing cardioversion of) Tj ETQq1 1 0.784314orgBT /Overlock 10	1.0	10
58	Stroke prevention in elderly patients with non-valvular atrial fibrillation in the BALKAN-CAF survey. European Journal of Clinical Investigation, 2020, 50, e13200.	3.4	5
59	ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Basic Epidemiology. Vnitřni Lekarství, 2017, 63, 25-30.	0.2	5
60	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. European Journal of Internal Medicine, 2022, 99, 45-56.	2.2	5
61	Association of anti phosphatidyl ethanolamine antibodies and low complement levels in systemic sclerosis patients – results of a cross-sectional study. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 476-481.	1.2	4
62	Preliminary data of familial hypercholesterolemia (FH) patients in Romania. Atherosclerosis, 2018, 277, 304-307.	0.8	4
63	Pharmacological Management of Heart Failure: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics, 2021, 28, e292-e298.	0.9	4
64	Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?. European Cardiology Review, 2016, 11, 115-117.	2.2	4
65	Acute rate control in atrial fibrillation: an urgent need for the clinician. European Heart Journal Supplements, 2022, 24, D3-D10.	0.1	4
66	Extended Antiphospholipid Antibodies Screening in Systemic Lupus Erythematosus Patients. Romanian Journal of Internal Medicine, 2015, 53, 321-328.	0.4	3
67	Symptom management strategies: Rhythm vs rate control in patients with atrial fibrillation in the Balkan region: Data from the BALKAN-CAF survey. International Journal of Clinical Practice, 2021, 75, e14080.	1.7	3
68	The dynamic nature of ventricular tachycardia initiation. Drugs of Today, 2010, 46, 777.	1.1	3
69	Rhythm Control in AF: Have We Reached the Last Frontier?. European Cardiology Review, 2019, 14, 77-81.	2.2	3
70	Pharmacological Management of Atrial Fibrillation: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics, 2022, 29, e18-e25.	0.9	3
71	ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Rationale and Design. Vnitřni Lekarství, 2017, 63, 43-48.	0.2	3
72	P Wave Signal-Averaged Electrocardiography in Patients with Chronic Obstructive Pulmonary Disease. Romanian Journal of Internal Medicine, 2015, 53, 315-320.	0.4	2

#	ARTICLE	IF	CITATIONS
73	Role of signal-averaged electrocardiography and ventricular late potentials in patients with chronic obstructive pulmonary disease. Romanian Journal of Internal Medicine, 2015, 53, 133-139.	0.4	2
74	Sudden Cardiac Death and Ventricular Arrhythmias. , 2016, , 3-25.		2
75	Transseptal Leftventricular Endocardial Pacing is an Alternative Technique in Cardiac Resynchronization Therapy. One Year Experience in a High Volume Center. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2016, 54, 121-128.	0.6	2
76	Highlights from the International Journal of Cardiology Heart & Vasculature: Heart failure, atrial fibrillation, coronary artery disease and myocardial infarction. IJC Heart and Vasculature, 2019, 25, 100443.	1.1	2
77	Treatment implications of renal disease in patients with atrial fibrillation: The BALKAN-FAF survey. Journal of Arrhythmia, 2020, 36, 863-873.	1.2	2
78	Quality indicators in the management of atrial fibrillation: the BALKAN-AF survey. International Journal of Cardiology, 2021, 333, 105-109.	1.7	2
79	Changing the Paradigm to Understand and Manage Atrial Fibrillation. , 2014, , 127-164.		2
80	Syncope due to autonomic insufficiency syndromes associated with orthostatic intolerance. Romanian Journal of Internal Medicine, 2000, 38-39, 3-19.	0.4	2
81	Facilitated electrical cardioversion: does the selection of the antiarrhythmic drug matter?. IJC Heart and Vasculature, 2019, 24, 100416.	1.1	1
82	Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. IJC Heart and Vasculature, 2020, 26, 100461.	1.1	1
83	Stroke Prevention in Atrial Fibrillation – The Use of NOACs in Everyday Clinical Practice. European Cardiology Review, 2015, 10, 76.	2.2	1
84	Left Ventricular noncompaction in a patient with systemic lupus erythematosus. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2019, 57, 78-82.	0.6	1
85	Stroke risk scores to predict hospitalization for acute decompensated heart failure in atrial fibrillation patients. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2020, 59, 73-82.	0.6	1
86	Myocardial involvement in systemic lupus erythematosus and systemic sclerosis--pulsed Doppler echocardiographic evaluation of left ventricular diastolic function. Romanian Journal of Internal Medicine, 1992, 30, 243-8.	0.4	1
87	Hemodynamic performances in patients treated with sotalol after electrical cardioversion of atrial fibrillation. Romanian Journal of Internal Medicine, 1997, 35, 19-27.	0.4	1
88	Corrigendum to: 'Summary Statement. EHRA Summit 2010 with the Participation of Central-Eastern European Countries: "ICD for Life" Initiative - Fighting against Sudden Cardiac Death in Emerging Economies' [Europace 2011;13:1209-10, doi:10.1093/europace/eur158]. Europace, 2011, 13, 1513-1513.	1.7	0
89	The net clinical benefit of the antithrombotic protection in prosthetic mechanical valves: Changing the paradigm. International Journal of Cardiology, 2018, 267, 77-78.	1.7	0
90	Non-traditional antiarrhythmic drugs as upstream and downstream dam for atrial fibrillation burden. IJC Heart and Vasculature, 2020, 29, 100610.	1.1	0

#	ARTICLE	IF	CITATIONS
91	Polypill revisited –“ Unity in diversity. IJC Heart and Vasculature, 2020, 29, 100607.	1.1	0
92	Wearable cardioverter-defibrillator in patients at risk of sudden cardiac death: consensus document from Kalarus et al. contradicts current guideline recommendations”Authors” reply. Europace, 2020, 22, 1442-1443.	1.7	0
93	Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authors” reply. Europace, 2020, 22, 1600-1601.	1.7	0
94	Defibrillators for prevention from sudden cardiac death: is it that easy?”Authors” reply. Europace, 2020, 22, 1298-1299.	1.7	0
95	Successful Thrombolysis for High-Risk Pulmonary Embolism in a Patient With Extensive Pemphigus Vulgaris. American Journal of Therapeutics, 2021, 28, 364-367.	0.9	0
96	Clinical Significance and Management of Arrhythmias. , 2020, , 379-422.		0
97	Beta-blockers as Antiarrhythmic Agents. , 2020, , 181-231.		0
98	Transcatheter radiofrequency ablation of atrioventricular by-pass tracts—a definitive cure of Wolff-Parkinson White syndrome. Romanian Journal of Internal Medicine, 1995, 33, 169-88.	0.4	0
99	Syncope in elderly patients—is there a place for endomyocardial biopsy?. Romanian Journal of Internal Medicine, 2013, 51, 67-71.	0.4	0
100	A debate on the certainty of etiology in a case of syncope. Romanian Journal of Internal Medicine, 2013, 51, 115-8.	0.4	0